Insulin-induced Lipohypertrophy in Patients with Type 1 Diabetes Mellitus Treated with an Insulin Pump
Table 1
Patients characteristics.
Variable
All patients (n = 79)
Patients with HbA1c <7% (n = 30)
Patients with HbA1c ≥ 7% (n = 48)
Age, years
28 (24–30.5)
29 (24.3–33.8)
25.5 (24–30)
0.21
Men, n (%)
40 (50.6)
16 (53.3)
23 (47.9)
0.82
Diabetes duration, years
15.0 (9–20)
12 (9–19)
16.5 (8.8–20)
0.44
Time in CSII, years
8.5 ± 4.8
9.2 ± 5.1
8.2 ± 4.6
0.37
HbA1c, %; mmol/mol
7.1 (6.7–8.1) 54 (51–65)
6.5 (6.3–6.8) 47.5 (45.4–50.8)
7.7 (7.3–8.8) 60.7 (56.3–72.7)
<0.001
BMI, kg/m2
24.5 ± 3.5
24.2 ± 3.2
24.7 ± 3.7
0.54
MDI before insulin pump, years
3 (2–8)
2 (1–5.8)
4 (2–12.3)
0.01
Hypothyroidism, n (%)
14 (17.7)
5 (16.7)
8 (16.3)
0.99
≥5 LH lesions on US, n (%)
41 (51.8)
13 (43.3)
24 (58.3)
0.29
HbA1c, hemoglobin A1c; CSII, continuous subcutaneous insulin infusion; BMI, body mass index; MDI, multiply insulin injection; LH, lipohyperthropy. For the comparison of patients with HbA1c < 7% and ≥7%.
